Outcome | Phase one | Phase two | p Value |
---|---|---|---|
Days-to-result (IQR) | |||
Definite TB | 6 (1–29) | 0 (0–1) | <0.001 |
Smear-negative TB | 29 (18–41) | 0 (0–0) | <0.001 |
Proportion on treatment (positive over total; %) | 26 (17/67) | 36 (26/73) | 0.196 |
Proportion who initiated treatment empirically* | 79 (11/14) | 28 (10/25) | 0.026 |
Proportion of all patients in each phase who initiated treatment according to final microbiological diagnosis (positive over total; %) | |||
Definite TB | 41 (7/17) | 68 (15/23) | 0.150 |
Possible-TB | 59 (10/17) | 42 (11/26) | 0.313 |
Days to treatment initiation (IQR) | |||
All patients | 10 (1–49) | 4 (0–16) | 0.330 |
Definite TB | 5 (1–57) | 2 (0–7) | 0.358 |
*Empirical anti-TB treatment is defined as the initiation of treatment on clinical grounds in the absence of positive smear microscopy, histology or culture result (in phase one), plus the absence of a poRIF result (phase two onlyRIF result (phase two only), /RIF result (phase two only)RIF result (phase two only), at time of treatment initiation. Three patients in phase one and one patient in phase two did not have information present regarding the date of treatment initiation.
TB, tuberculosis; IQR, interquartile range.